Finerenone, BAY 94-8862, placebo equal to test product except active substance clinical trials

(22267) A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes

This study is looking into a new medication called finerenone for people with long-term kidney disease caused by type 1 diabetes. We want to see if it works better than a dummy medicine (placebo) to slow down kidney damage over 6 months, alongside their usual care.